jRCT2080225134已完成3 期
MD-110 Phase 3 Study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multi-center, open-label, non-comparative study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 70age old under（—）
- 性别
- Female
入选标准
- •Diagnosed with primary invasive breast cancer, etc.
排除标准
- •Double cancer, etc.
结局指标
主要结局
-
safety efficacy Efficacy: The duration of severe neutropenia (DSN) Safety: Adverse Reactions
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
未知
3 期
Phase 3 Clinical Trial with MD-0901Mild to moderate active ulcerative colitisJPRN-jRCT2080222425MOCHIDA PHARMACEUTICAL CO., LTD.250
未知
3 期
Active Phase Study with MD-0901 -Phase 3 Clinical Trial in Patients with Mild to Moderate Active Ulcerative ColitisMild to moderate active ulcerative colitisJPRN-jRCT2080221343MOCHIDA PHARMACEUTICAL CO., LTD.228
招募中
不适用
TO-209 Phase III Clinical StudyGrass PollinosisjRCT2041250027Torii Pharmaceutical Co.,Ltd760
进行中（未招募）
不适用
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
未知
3 期
KD-357 Phase III Studypreexposure prophylaxis against rabiesJPRN-jRCT2080222145The Chemo-Sero-Therapeutic Research Institute200